An anti-diabetic nutraceutical, Cadalmin, developed by Indian Council of Agriculture Research (ICAR)-Central Marine Fisheries Research Institute (CMFRI), is expected to be available for the public soon.
Director, ICAR-CMFRI A. Gopalakrishnan, had recently signed a Memorandum of Understanding with a Hyderabad-based company for commercial production and marketing of Cadalmin in Kochi. The product is effective to combat type-2 diabetes, said a statement issued by the CMFRI here.
Cadalmin, which has 100 per cent natural marine bioactive ingredients from selected seaweeds, would be made available in 500 mg capsules by the company.
The active ingredients in the product would be packed in plant-based capsules to meet the dietary needs of the large vegetarian population in India and abroad.
The nutraceutical is prepared from seaweeds, which are commonly available in the Indian coastal waters.
Seaweeds are the natural bounty of the sea and are known for their medicinal properties.
ICAR-CMFRI is in the process of developing more health products from seaweeds towards their utilisation based on the national policy to harness the potential of the natural wealth in the Indian coastal waters.
The institute is also in the process of standardising and promoting seaweed farming all along the Indian coasts as a livelihood option for the coastal communities.
The product was officially released by Union Minister for Agriculture Radha Mohan Singh in July 2015 at a function organised in Patna during the ICAR Foundation Day celebrations.
ICAR-CMFRI is in the process of developing more health products from seaweeds
